GlassScriptPhysician profile
Meagan Donner
NPI 1124648118
$7,207.21
in general payments reported to CMS, 2019-2025
24 companies · $2,286 in 2025
The $2,286 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $432 · 2022: $927 · 2023: $1,322 · 2024: $2,240 · 2025: $2,286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,651 · Education: $197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,650.97 |
| Education | $197.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,340.22 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Abbvie INC. | $864.04 | 2021-2025 | |
| Axsome Therapeutics, INC. | $754.03 | 2022-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $685.25 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $557.22 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Tris Pharma INC | $438.77 | 2023-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Alkermes, INC. | $386.48 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Vanda Pharmaceuticals INC. | $309.59 | 2021-2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $273.36 | 2022-2025 | Uzedy, Austedo Xr |
| Ironshore Pharmaceuticals INC. | $207.29 | 2022-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $199.78 | 2022-2025 | Qelbree |
| Biogen, INC. | $141.60 | 2025 | Zurzuvae |
| Corium, LLC | $125.41 | 2021-2023 | Azstarys |
| Eisai INC. | $115.18 | 2025 | |
| Neos Therapeutics, LP | $109.10 | 2021-2025 | Adzenys Xr-Odt, Exxua |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $108.11 | 2021-2025 | |
| Lundbeck LLC | $106.21 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $100.82 | 2021-2025 | Trintellix |
| Collegium Pharmaceutical, INC. | $93.86 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $88.58 | 2024-2025 | Xelstrym, Secuado |
| Tempus Ai, INC | $83.31 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $51.51 | 2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $40.12 | 2023 | Quviviq |
| Jazz Pharmaceuticals INC. | $27.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meagan Donner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.